Medication approval journey
bupropion (Wellbutrin SR)
Approved for Major depressive disorder
Before changing anything
Stopping abruptly causes withdrawal effects that can be severe
Withdrawal effects vary a lot across this group but are real. Any change should be prescriber-supervised rather than abrupt.
How long the trials actually ran
The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.
The approval, step by step
Step 1
What the approval was actually based on
Which studies did the FDA rely on, how long did they run, and who was in them?
The efficacy of the immediate-release formulation of bupropion in the treatment of major depressive disorder was established in two 4-week, placebo-controlled trials in adult inpatients with MDD (Trials 1 and 2 in Table 6) and in one 6-week, placebo-controlled trial in adult outpatients with MDD (Trial 3 in Table 6).
Step 2
The approval
When was it approved, under what application, and by whose review?
- Approved
- October 4, 1996
- Application
- NDA020358
- Review
- STANDARD
Step 3
What was added after it was on the market
Which warnings arrived only after millions of people were already taking it?
Step 4
What independent research has found since
What has been learned by people who were not selling it?
Step 5
What still is not known
Which questions you might reasonably have has nobody answered yet?
Open bupropion (Wellbutrin SR) in Resolv
The app has the full approval journey, the resources behind it, and people working through the same questions.
